Meningococcemia natural history, complications and prognosis
Meningococcemia Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Meningococcemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Meningococcemia natural history, complications and prognosis |
FDA on Meningococcemia natural history, complications and prognosis |
CDC on Meningococcemia natural history, complications and prognosis |
Meningococcemia natural history, complications and prognosis in the news |
Blogs on Meningococcemia natural history, complications and prognosis |
Risk calculators and risk factors for Meningococcemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Overview
Natural History
- Before antibiotics the case fatality rate was over 50%, particularly dangerous in infants and elderly (84% and 72% respectively). Now it is often as low as 8% in major medical centers.
Risk Stratification and Prognosis
- Current vaccines have polysaccharides of groups A, C, Y, and W-135. No vaccine available presently for group B disease since the polysaccharide is not sufficiently immunogenic to produce a reliable antibody response in humans to be effective.
- Rates of meningococcus in US college students as a whole 0.7 per 100,000.
- Rates of meningococcus in US persons aged 18-23 not in college 1.5 per 100,000.
- Rates of freshmen living in dormitories 4.6 per 100,000.
- Rates for college students in UK 13.2 per 100,000 versus those not in college of 5.5 per 100,000.